Mersana Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities
Segment and consolidated net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Loss on disposal of fixed assets
Net amortization of premiums and discounts on marketable securities
Stock-based compensation
Change in deferred rent
Non-cash operating lease expense
Other non-cash items
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses
Operating lease right-of-use assets
Operating lease liabilities
Deferred revenue
Other liabilities

Net cash used in operating activities
Cash flows from investing activities
Maturities of marketable securities
Purchase of marketable securities
Purchase of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities
Net proceeds from at-the-market facilities
Public Stock Offering
At market equity offering program (2018 ATM)
At Market Equity Offering Program

Proceeds from exercise of stock options
Proceeds from purchases of common stock under ESPP
Payment of employee tax obligations related to vesting of restricted stock units
Proceeds from issuance of debt, net of issuance costs
Repayment of debt
Payments under finance lease obligations
Net cash provided by financing activities
(Decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental cash flow information:
Cash paid for income taxes
Fair value of common stock retired in exchange for issuance of pre-funded warrants
Purchases of property and equipment in accounts payable and accrued expenses
Debt financing costs in accrued expenses
Common stock issuance costs in accounts payable and accrued expenses
Cash paid for interest
Right-of-use assets obtained in exchange for operating lease liabilities
Right-of-use assets obtained in exchange for financing lease liabilities
Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606

Comments